重症ループス漿膜炎・心不全に対する分子状水素の補助的使用：免疫調節と疲労軽減に関する症例報告
A 51-year-old woman with systemic lupus erythematosus (SLE) and concurrent acute decompensated heart failure was managed initially with corticosteroids and immunomodulatory agents. Molecular hydrogen was subsequently introduced as an adjunct intervention. Over several months of follow-up, reductions were documented in anti-dsDNA antibodies, anti-Ro52 antibodies, and Pro-BNP levels, alongside favorable changes in T-cell and B-cell subset distributions. Cardiac function improved, and the patient reported marked alleviation of fatigue. Corticosteroid tapering was achieved while disease stability was maintained under continued hydrogen administration. The authors suggest that molecular hydrogen may contribute to immune modulation and symptom relief in autoimmune conditions, and call for controlled studies to clarify its role.
Molecular hydrogen is proposed to exert antioxidant and anti-inflammatory effects that modulate T-cell and B-cell subset distributions, thereby reducing autoantibody production (anti-dsDNA, anti-Ro52) and attenuating inflammatory cardiac dysfunction.
The delivery route is not clearly identifiable from this paper. For hydrogen intake, inhalation is the most efficient route; inhalation, however, carries explosion risk (empirical LFL of 10%; high-concentration devices are not recommended).
See also:
https://h2-papers.org/en/papers/40010949